Sernova Biotherapeutics Inc
SVA.TO
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.14% | 33.90% | 24.88% | -1.54% | 16.27% |
| Total Depreciation and Amortization | -73.16% | 4.96% | 56.86% | -1.81% | -12.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 216.53% | -177.80% | 5.52% | -2.53% | 8.96% |
| Change in Net Operating Assets | -92.53% | -53.46% | 63.99% | -59.60% | 1,183.58% |
| Cash from Operations | -18.18% | -12.93% | 52.29% | -69.52% | 62.35% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | 24.86% | 91.40% | -3.89% |
| Cash from Investing | -- | -100.00% | 24.86% | 91.40% | -3.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.19% | 0.00% | 0.00% | 2.55% | 0.69% |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 125.56% | -470.61% | -64.56% | -- | -- |
| Cash from Financing | -99.56% | 18,657.81% | -84.38% | 484.06% | -136.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -564.87% | -37.02% | 151.02% | -38.15% | 75.43% |